Advertisement
Singapore markets close in 59 minutes

  • Straits Times Index

    3,297.50
    +24.78 (+0.76%)
     

  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     

  • Hang Seng

    17,154.23
    +325.30 (+1.93%)
     

  • FTSE 100

    8,076.63
    +31.82 (+0.40%)
     

  • Bitcoin USD

    66,654.57
    +409.82 (+0.62%)
     

  • CMC Crypto 200

    1,416.02
    -8.08 (-0.57%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • Dow

    38,503.69
    +263.71 (+0.69%)
     

  • Nasdaq

    15,696.64
    +245.33 (+1.59%)
     

  • Gold

    2,333.90
    -8.20 (-0.35%)
     

  • Crude Oil

    83.36
    0.00 (0.00%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • FTSE Bursa Malaysia

    1,570.50
    +8.86 (+0.57%)
     

  • Jakarta Composite Index

    7,164.27
    +53.46 (+0.75%)
     

  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Biotech Stock Tests Buy Zone, Gets New Approval For Asthma Drug Relvar Ellipta

MATTHEW GALGANI
Updated
Biotech Stock Tests Buy Zone, Gets New Approval For Asthma Drug Relvar Ellipta

GlaxoSmithKline[ticker symb=GSK] partner Innoviva[ticker symb=INVA] is trying to buck the market correction and finish a new base. The biotech stock recently received new European Union approval for Relvar Ellipta, an asthma drug Innoviva developed with GSK. Last month, London-based GSK and California-based Innoviva announced that the European Commission approved a label upgrade for Relvar Ellipta. Known as Breo Ellipta in...

Continue reading